{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:22:32Z","timestamp":1787030552133,"version":"build-2736575974"},"reference-count":38,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2019.10410","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T03:18:43Z","timestamp":1559186323000},"source":"Crossref","is-referenced-by-count":11,"title":["Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T\u2011cell lymphoma"],"prefix":"10.3892","author":[{"given":"Huilai","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Lymphoma, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhe","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongli","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, College of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tianjin Union Medical Center, The Affiliated Hospital of Nankai University, Tianjin 300121, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Sino\u2011US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"key":"key20200714090916_b1-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2119\/molmed.2010.00103","article-title":"High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients","volume":"17","author":"Cai","year":"2011","journal-title":"Mol Med"},{"key":"key20200714090916_b2-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/1471-2407-9-461","article-title":"Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma","volume":"9","author":"He","year":"2009","journal-title":"BMC Cancer"},{"key":"key20200714090916_b3-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"390482","DOI":"10.1155\/2013\/390482","article-title":"High expression of H3K27me3 is an independent predictor of worse outcome in patients with urothelial carcinoma of bladder treated with radical cystectomy","volume":"2013","author":"Liu","year":"2013","journal-title":"Biomed Res Int"},{"key":"key20200714090916_b4-ol-0-0-10410","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica"},{"key":"key20200714090916_b5-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3892\/ijo.2013.2062","article-title":"High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non-small cell lung cancer","volume":"43","author":"Chen","year":"2013","journal-title":"Int J Oncol"},{"key":"key20200714090916_b6-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1002\/mc.20413","article-title":"Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers","volume":"47","author":"Wei","year":"2008","journal-title":"Mol Carcinog"},{"key":"key20200714090916_b7-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.3390\/nu6104273","article-title":"The role of dietary histone deacetylases (HDACs) inhibitors in health and disease","volume":"6","author":"Bassett","year":"2014","journal-title":"Nutrients"},{"key":"key20200714090916_b8-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"key":"key20200714090916_b9-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cr.2011.22","article-title":"Regulation of chromatin by histone modifications","volume":"21","author":"Bannister","year":"2011","journal-title":"Cell Res"},{"key":"key20200714090916_b10-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene"},{"key":"key20200714090916_b11-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.biocel.2008.09.008","article-title":"Histone deacetylase inhibitors: Anticancer compounds","volume":"41","author":"Smith","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"key20200714090916_b12-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1593\/neo.08474","article-title":"Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas","volume":"10","author":"Weichert","year":"2008","journal-title":"Neoplasia"},{"key":"key20200714090916_b13-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/pros.20022","article-title":"Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer","volume":"59","author":"Halkidou","year":"2004","journal-title":"Prostate"},{"key":"key20200714090916_b14-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1158\/1078-0432.CCR-07-0990","article-title":"Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: Specific role of class I histone deacetylases in vitro and in vivo","volume":"14","author":"Weichert","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20200714090916_b15-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(08)70004-4","article-title":"Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis","volume":"9","author":"Weichert","year":"2008","journal-title":"Lancet Oncol"},{"key":"key20200714090916_b16-ol-0-0-10410","first-page":"1439","article-title":"Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer","volume":"21","author":"Wang","year":"2009","journal-title":"Oncol Rep"},{"key":"key20200714090916_b17-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/1471-2407-8-381","article-title":"Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer","volume":"8","author":"Fritzsche","year":"2008","journal-title":"BMC Cancer"},{"key":"key20200714090916_b18-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1365-2559.2008.03109.x","article-title":"Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma","volume":"53","author":"Marquard","year":"2008","journal-title":"Histopathology"},{"key":"key20200714090916_b19-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","article-title":"Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas","volume":"54","author":"Marquard","year":"2009","journal-title":"Histopathology"},{"key":"key20200714090916_b20-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2007.09.026","article-title":"H3K27 demethylases, at long last","volume":"131","author":"Swigut","year":"2007","journal-title":"Cell"},{"key":"key20200714090916_b21-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","article-title":"The Polycomb complex PRC2 and its mark in life","volume":"469","author":"Margueron","year":"2011","journal-title":"Nature"},{"key":"key20200714090916_b22-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1076997","article-title":"Role of histone H3 lysine 27 methylation in Polycomb-group silencing","volume":"298","author":"Cao","year":"2002","journal-title":"Science"},{"key":"key20200714090916_b23-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","article-title":"Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"Simon","year":"2008","journal-title":"Mutat Res"},{"key":"key20200714090916_b24-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1182\/blood-2010-04-280149","article-title":"EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis","volume":"116","author":"Velichutina","year":"2010","journal-title":"Blood"},{"key":"key20200714090916_b25-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF00573019","article-title":"Proceedings: Prognosis of non-Hodgkin's lymphomas with special emphasis on the staging classification","volume":"83","author":"Musshoff","year":"1975","journal-title":"Z Krebsforsch Klin Onkol Cancer Res Clin Oncol"},{"key":"key20200714090916_b26-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20200714090916_b27-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood-2011-07-367243","article-title":"Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms","volume":"119","author":"Score","year":"2012","journal-title":"Blood"},{"key":"key20200714090916_b28-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.2651","article-title":"Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia","volume":"18","author":"Ntziachristos","year":"2012","journal-title":"Nat Med"},{"key":"key20200714090916_b29-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1101\/gad.186411.111","article-title":"A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia","volume":"26","author":"Simon","year":"2012","journal-title":"Genes Dev"},{"key":"key20200714090916_b30-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.3109\/10428194.2014.968780","article-title":"Enhancer of zeste homolog 2 is widely expressed in T-cell neoplasms, is associated with high proliferation rate and correlates with MYC and pSTAT3 expression in a subset of cases","volume":"56","author":"Shi","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"key20200714090916_b31-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.18632\/oncotarget.3120","article-title":"HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma","volume":"6","author":"Johnson","year":"2015","journal-title":"Oncotarget"},{"key":"key20200714090916_b32-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"18475","DOI":"10.1073\/pnas.1012946107","article-title":"A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage","volume":"107","author":"Chou","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20200714090916_b33-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1002\/ijc.28852","article-title":"Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas","volume":"135","author":"Zappasodi","year":"2014","journal-title":"Int J Cancer"},{"key":"key20200714090916_b34-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejcb.2004.12.010","article-title":"Histone deacetylase inhibitors and cancer: From cell biology to the clinic","volume":"84","author":"Hess-Stumpp","year":"2005","journal-title":"Eur J Cell Biol"},{"key":"key20200714090916_b35-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4161\/epi.3.1.5736","article-title":"HDACs and HDAC inhibitors in colon cancer","volume":"3","author":"Mariadason","year":"2008","journal-title":"Epigenetics"},{"key":"key20200714090916_b36-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","article-title":"Histone deacetylases and cancer","volume":"6","author":"Barneda-Zahonero","year":"2012","journal-title":"Mol Oncol"},{"key":"key20200714090916_b37-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3892\/mco.2013.146","article-title":"Significance of clinical factors as prognostic indicators for patients with peripheral T-cell non-Hodgkin lymphoma: A retrospective analysis of 252 cases","volume":"1","author":"Xie","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"key20200714090916_b38-ol-0-0-10410","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T05:52:47Z","timestamp":1594705967000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2019.10410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":38,"URL":"https:\/\/doi.org\/10.3892\/ol.2019.10410","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]}}}